NMN vs Urolithin A 2026: NAD+ Restoration vs Mitophagy, Evidence, Cost, and Whether to Stack Both

What NMN Does: NAD+ Restoration

NMN (nicotinamide mononucleotide) converts to NAD+ inside cells through a one-step enzymatic reaction. Multiple human trials at 250 to 1,250 mg daily show that oral NMN raises blood NAD+ levels. The downstream effects include support for sirtuin activity, DNA repair, and mitochondrial function.

NAD+ is a coenzyme present in every cell. It participates in hundreds of metabolic reactions, including those that produce ATP in mitochondria. NAD+ levels decline measurably with age, by some estimates 50% or more by age 60. The hypothesis behind NMN supplementation is that restoring NAD+ to more youthful levels can slow or partially reverse age-related cellular dysfunction.

The trial evidence supports the first step of that hypothesis: NMN does raise NAD+. A 60-day dose-response study found NAD+ increased in proportion to the dose (300, 600, and 900 mg) and six-minute walking distance improved in all NMN groups (Yi et al., 2023). A 10-week trial found improved muscle insulin sensitivity at 250 mg (Yoshino et al., 2021). Safety has been demonstrated up to 1,250 mg daily for four weeks (Fukamizu et al., 2022).

What the evidence does not yet show is whether raising NAD+ actually extends healthspan or lifespan in humans. A 2026 systematic review of 113 NAD-related studies found clear biological activity but inconclusive evidence for anti-aging outcomes (Gallagher et al., 2026). NMN raises the level of a molecule that matters. Whether that translates into living longer or better is an open question. Our What Is NMN? and NMN dosage guide cover the compound in detail.

What Urolithin A Does: Mitophagy Activation

Urolithin A triggers mitophagy, the cellular process that identifies damaged mitochondria, breaks them down, and recycles their components so new, functional mitochondria can replace them. This is mechanistically distinct from NMN. While NMN fuels the mitochondria you have, Urolithin A clears out the ones that no longer work properly.

Urolithin A is a postbiotic compound that the human gut can produce from ellagitannins found in pomegranates, walnuts, and berries. The problem is that not everyone's gut microbiome produces it efficiently: studies suggest only about 40% of people can convert dietary ellagitannins to Urolithin A at meaningful levels. Supplementation bypasses this limitation.

The first human study established safety and showed that oral Urolithin A at 250 to 2,000 mg induced a molecular signature of improved mitochondrial and cellular health, including upregulation of mitophagy-related gene expression (Andreux et al., 2019).

A 2022 randomized trial in older adults with muscle weakness tested 1,000 mg daily for 4 months and found improved muscle endurance (measured by a six-minute walk test and hand-grip fatigability), along with decreased plasma biomarkers associated with mitochondrial dysfunction and inflammation (Liu et al., 2022). A separate 2022 trial found improvements in muscle strength, exercise performance, and mitochondrial biomarkers with Urolithin A supplementation (Singh et al., 2022).

A 2025 study evaluated Urolithin A supplementation on running performance, recovery, and mitochondrial biomarkers in healthy adults, extending the evidence to younger, active populations (Whitfield et al., 2025). These trials collectively make Urolithin A one of the better-evidenced longevity compounds for measurable physical performance outcomes.

Head-to-Head Comparison: Different Mechanisms, Complementary Targets

NMN and Urolithin A address two different failure modes of aging mitochondria. NMN restores the fuel supply (NAD+). Urolithin A clears out the broken engines (damaged mitochondria via mitophagy). Neither replaces the other. No head-to-head trial exists.

Category	NMN	Urolithin A
Primary mechanism	Restores NAD+ (fuel for mitochondria, sirtuins, DNA repair)	Triggers mitophagy (clears damaged mitochondria)
Target problem	NAD+ decline with age	Accumulation of dysfunctional mitochondria
Typical daily dose	250–500 mg	500–1,000 mg
Number of human RCTs	10+ (various doses and populations)	4–5 (Amazentis/Mitopure-sponsored)
Measured physical performance outcome	Walking distance, ventilatory thresholds (small effects)	Muscle endurance, grip strength, walking distance (moderate effects)
Measured biomarker changes	Blood NAD+ increase (consistent)	Mitochondrial gene expression, inflammatory markers
Monthly cost	$17–$69 (depending on brand)	$50–$90 (Mitopure/Timeline is the most studied)
Natural source	Found in trace amounts in edamame, broccoli, avocado	Gut microbiome converts pomegranate ellagitannins (varies by person)
FDA regulatory status	Dietary supplement (since Sep 2025 reversal)	GRAS (Mitopure/Amazentis received GRAS in 2020)

The most notable difference in the table is the performance outcome evidence. Urolithin A's trials measured muscle endurance and strength with moderate, statistically significant improvements in older adults. NMN's performance findings are more modest: a walking distance improvement in one trial, ventilatory threshold changes in runners at higher doses. For someone choosing based on which compound has the strongest direct evidence for feeling or performing better, Urolithin A currently has a slight edge, though the trials were sponsored by its manufacturer, Amazentis.

The Stacking Logic: Why Longevity Researchers Recommend Both

NMN provides the NAD+ that healthy mitochondria need to function. Urolithin A removes the damaged mitochondria that waste energy and produce harmful reactive oxygen species. Together, they address mitochondrial aging from two sides: better fuel supply and cleaner machinery.

The analogy that appears across longevity forums: NMN is like refueling the engine, while Urolithin A is like replacing the worn-out parts. If you only refuel a broken engine, it runs poorly on good fuel. If you only replace parts but starve the new engine of fuel, it still cannot run. The logic for stacking both is that addressing both failure modes simultaneously should produce better mitochondrial function than addressing either alone.

No published trial has tested NMN plus Urolithin A against either alone. Several supplement brands now sell combination products (NMN + Urolithin A in one capsule), and at least one clinical trial is investigating a brain longevity supplement containing Urolithin A alongside other compounds. Until a head-to-head combination trial is published, the stacking logic is biochemically sound but clinically unproven.

A 2026 meta-analysis of NMN supplementation found the compound well tolerated (Yang et al., 2026). Urolithin A has GRAS status and was well tolerated in all published trials up to 2,000 mg. No interaction between the two has been reported in any study or pharmacological analysis. Taking both appears safe based on current data.

Where Each Compound Comes From

NMN is synthesized in a lab, usually from nicotinamide and ribose, and is available from dozens of suppliers. Urolithin A is also lab-synthesized for supplements, because dietary conversion from pomegranate is unreliable. The leading clinical-grade Urolithin A is Mitopure, made by Amazentis in Switzerland.

NMN's supply chain is broader. Multiple manufacturers (including Effepharm, which makes the Uthever brand) produce pharmaceutical-grade NMN powder. This competition keeps prices lower and gives buyers many brand options. The raw material is the same β-NMN molecule regardless of supplier; what differs is purity testing and quality control.

Urolithin A's supply chain is narrower. Amazentis holds patents on the production process and the Mitopure ingredient. Generic Urolithin A supplements are appearing on the market, but they were not used in the published clinical trials. Buying a generic Urolithin A product means trusting the manufacturer's quality without the clinical trial validation that Mitopure carries. That is a meaningful difference for a compound where all the human evidence comes from one specific formulation.

The parallel to NMN is instructive: NMN trials used various formulations from different labs, so the evidence is less tied to a single supplier. Urolithin A's evidence is essentially Mitopure's evidence. Whether generic Urolithin A works the same way is an assumption, not a tested fact.

Safety Profile: What We Know for Each

Both compounds are well tolerated in published trials. NMN has been tested up to 1,250 mg daily for four weeks. Urolithin A has GRAS status and has been tested up to 2,000 mg in single doses and 1,000 mg daily for four months. No serious adverse events have been reported for either.

NMN's safety data spans multiple independent research groups. A 2026 meta-analysis pooling data across trials found oral NMN generally well tolerated without patterns of adverse events (Yang et al., 2026). The main reported side effect is mild gastrointestinal discomfort at higher doses, which is common for many supplements.

Urolithin A received GRAS (Generally Recognized As Safe) status from an expert panel review in 2020 for the Mitopure formulation. The first human study tested single doses up to 2,000 mg and 28-day supplementation at multiple dose levels without clinically significant adverse effects (Andreux et al., 2019). Subsequent trials at 500 to 1,000 mg daily for up to four months confirmed the favorable safety profile.

Neither compound has long-term safety data (years of daily use). Both are relatively new as mainstream supplements. People who are pregnant, breastfeeding, or taking prescription medication should consult a doctor before starting either. Our NMN side effects guide covers NMN-specific safety in detail.

The Age Factor: When Each Matters Most

NAD+ decline begins in the 30s and accelerates through the 40s and beyond. Mitophagy efficiency also declines with age. Both processes contribute to the aging phenotype. The earlier you address them, the more mitochondrial function you may preserve, but the evidence for preventive use in younger adults is weaker than for corrective use in older adults.

NMN trials have enrolled adults from their 20s to their 70s. The clearest benefits appear in middle-aged and older adults, where NAD+ decline is most pronounced. For a 30-year-old with normal NAD+ levels, raising them further may have diminishing returns. For a 55-year-old with NAD+ levels 40-50% below peak, restoration has a stronger rationale.

Urolithin A trials focused on adults aged 40 to 80, with the strongest physical performance results in those over 60 with measurable muscle weakness. The Liu trial specifically enrolled sedentary older adults with declining physical function, exactly the population where accumulated mitochondrial damage is most advanced.

For a younger, active person: creatine (for performance) and a basic health stack may deliver more value than either NMN or Urolithin A. For someone over 45 who wants to invest in cellular maintenance, both NMN and Urolithin A have age-relevant evidence, with the caveat that long-term outcomes remain unproven.

Cost Comparison: What Each Adds to Your Monthly Spend

NMN ranges from $17 to $69 per month depending on brand and dose. Urolithin A costs roughly $50 to $90 per month for the most studied form (Mitopure by Timeline). A stack of both runs $67 to $159 per month. That is a meaningful supplement budget.

Supplement	Monthly cost range	Most studied form
NMN 500 mg/day	$17–$69	Multiple brands (Uthever NMN powder is common)
Urolithin A 500 mg/day	$50–$90	Mitopure (Amazentis/Timeline), used in all major RCTs
NMN + Urolithin A stack	$67–$159	No studied combination product

If budget forces a choice: for someone whose primary goal is mitochondrial health and physical performance in middle or older age, Urolithin A's trial evidence for measurable outcomes is currently stronger per dollar. For someone whose primary goal is broad cellular maintenance (NAD+ supports sirtuins, PARPs, and immune function beyond mitochondria), NMN addresses a wider set of pathways. Neither choice is wrong; they optimize for different priorities.

Our best NMN supplements guide compares NMN options by brand. For Urolithin A, the most studied brand is Timeline (Mitopure), though generic Urolithin A supplements are now available at lower prices with less clinical backing.

Sponsorship and Evidence Quality: A Note

All major Urolithin A human trials have been sponsored by Amazentis, the company that makes Mitopure. NMN trials come from multiple independent research groups. Sponsor-funded trials are not invalid, but they should be read with awareness that the funder has a commercial interest in positive results.

This is an important context for the comparison. NMN's evidence comes from labs in Japan, the US, China, and Switzerland, funded by a mix of academic grants, supplement companies, and government agencies. Urolithin A's human evidence comes almost entirely from Amazentis-sponsored trials. The studies are well-designed (randomized, double-blind, placebo-controlled) and published in reputable journals (Nature Metabolism, Cell Reports Medicine, JAMA Network Open). The concern is not quality but diversity: all the evidence traces back to one company's research program.

Independent replication of Urolithin A's results, by a lab with no financial ties to Amazentis, would substantially strengthen the evidence base. Until that happens, Urolithin A's trial data is strong but single-source. NMN's trial data is more modest per study but comes from independent researchers worldwide.

What Each Compound Does NOT Do

NMN does not clear damaged mitochondria. Urolithin A does not raise NAD+. Neither has demonstrated lifespan extension in humans. Neither is a substitute for exercise, sleep, or a good diet. Understanding what these compounds cannot do is as important as knowing what they might.

NMN marketing often implies broad anti-aging benefits. The evidence shows it raises NAD+ and, in some trials, improves a few metabolic markers. It does not reverse aging. It does not prevent cancer. It does not replace cardiovascular exercise for heart health. A 2026 review stated this clearly: biological activity is demonstrated; clinical anti-aging effectiveness is not (Gallagher et al., 2026).

Urolithin A marketing focuses on "cellular renewal" and "mitochondrial recycling." The trials show it induces mitophagy-related gene expression changes and improves certain physical performance measures in older adults. It does not regenerate organs. It does not reverse sarcopenia on its own. The performance improvements, while statistically significant, were modest: an extra 16 meters in a six-minute walk test, for example.

Both compounds are best understood as potential tools for cellular maintenance, like changing the oil in a car. It is worth doing, and it may extend the engine's useful life, but it does not rebuild the engine, and it does not matter much if you never drive the car. Exercise, sleep, nutrition, and stress management remain the foundation. Supplements like NMN and Urolithin A are the top of the pyramid, not the base.

The Mitochondrial Aging Framework: Where NMN and Urolithin A Fit

Mitochondrial aging involves two related processes: declining NAD+ reduces mitochondrial fuel supply, and declining mitophagy allows damaged mitochondria to accumulate. NMN addresses the first. Urolithin A addresses the second. Together, they cover the two main arms of mitochondrial aging.

This framework explains why longevity researchers increasingly view NMN and Urolithin A as a complementary pair rather than competitors. Other compounds fit into the same framework: CoQ10 supports the electron transport chain directly, PQQ may stimulate mitochondrial biogenesis, and exercise activates both NAD+ production and mitophagy naturally. The supplement stack is a partial substitute for what exercise does, partial because no pill replicates the full signaling cascade of physical activity.

For someone who exercises regularly, eats well, and sleeps enough, adding NMN and Urolithin A is a marginal optimization. For someone who does not exercise, these supplements are trying to patch a system that is declining for reasons they do not address. The supplements are more effective in the context of a healthy lifestyle, not as a replacement for one.

Our What Is NMN? guide explains NAD+ biology in depth. For a broader view of the longevity supplement field, our best NMN supplements guide compares NMN options, and our NMN product page shows our own offering.

Can You Get These From Food Instead of Supplements?

Neither compound is realistically obtainable from food at supplement-equivalent doses. NMN exists in trace amounts in edamame, broccoli, and avocado, but you would need to eat kilograms daily to match a 500 mg dose. Urolithin A is produced by gut bacteria from pomegranate and walnut ellagitannins, but only about 40% of people have the microbiome to make meaningful amounts.

For NMN, the food argument collapses on arithmetic. Edamame contains among the highest natural NMN levels of any food, at roughly 0.5 to 2 milligrams per 100 grams. To reach the 250 to 500 mg used in trials, you would need to eat tens of kilograms of edamame per day. Broccoli, cabbage, avocado, and raw beef contain even less. Dietary NMN contributes to baseline NAD+ metabolism, but it cannot approach a supplemental dose.

Urolithin A is more nuanced because it is not consumed directly. Your gut bacteria produce it from ellagitannins in pomegranates, walnuts, strawberries, and raspberries. The catch is that the conversion depends on having the right bacterial species. Research suggests only about 40% of people are efficient Urolithin A producers; the rest convert little or none regardless of how much pomegranate they eat. This is precisely why direct Urolithin A supplementation exists: it bypasses the microbiome lottery. A non-producer eating pomegranate daily gets the fiber and polyphenols but little Urolithin A, while a supplement delivers a known dose to everyone.

The practical takeaway: eating pomegranate, walnuts, and berries is healthy for many reasons and worth doing, but it is not a reliable substitute for Urolithin A supplementation if the mitophagy mechanism is what you want, because you cannot know whether you are one of the 40% who convert efficiently without testing. And no realistic diet substitutes for supplemental NMN at the levels tested in the clinical trials, however many servings of edamame or broccoli you manage to eat. If you want the specific effects studied in the trials, supplementation is the only route to trial-level doses. Our What Is NMN? guide covers NMN's dietary sources in more detail.

Who Should Choose Which, or Both

Choose NMN if your priority is broad NAD+ restoration for cellular maintenance. Choose Urolithin A if your priority is mitochondrial quality and measurable muscle performance. Choose both if your budget allows and you want to address aging mitochondria from two complementary angles.

The office worker over 40 who wants general vitality. NMN's NAD+ restoration supports a broader set of cellular functions (DNA repair, immune signaling, circadian rhythm). It is the more general-purpose longevity supplement of the two.

The active person over 50 noticing strength decline. Urolithin A has the stronger evidence for physical performance improvements in this demographic. The Liu and Singh trials tested exactly this population and found measurable gains.

The longevity optimizer with budget. Both. NMN fuels the new, healthy mitochondria that Urolithin A's mitophagy creates. The mechanistic synergy is logical even without a combination trial to prove it.

The budget-constrained buyer. NMN from a budget brand like Nutricost ($17/month) is the cheapest entry point into the longevity supplement space. Add Urolithin A later if results and budget align.

The Short Answer

NMN for broad cellular maintenance. Urolithin A for mitochondrial quality and physical performance in aging adults. Both if your budget allows and you want to address aging mitochondria from two sides.

If forced to pick one, the choice depends on age and goal. Under 45 with general wellness goals: NMN, because NAD+ restoration supports a wider range of cellular functions. Over 50 with noticeable physical decline: Urolithin A has the stronger performance outcome data in that demographic. Both together is the most complete stack for mitochondrial aging, at a combined $67 to $159 per month that not everyone can justify on current evidence.

Products We Sell

YourHealthier sells an NMN capsule but does not currently sell Urolithin A. We disclose this because our commercial interest is in one of the two supplements compared. This article evaluates both based on published evidence.

NMN vs Urolithin A FAQ

Common questions about the comparison.

Is NMN or Urolithin A better for anti-aging?

They address different aging mechanisms. NMN restores NAD+ for sirtuins and DNA repair. Urolithin A clears damaged mitochondria. Neither has proven anti-aging effects in long-term human studies. Both have strong biological rationale.

Can I take NMN and Urolithin A together?

Yes. No adverse interaction has been identified. They work through non-overlapping pathways. Several brands now sell combination products.

Which has more clinical evidence?

NMN has more total trials. Urolithin A has stronger evidence for measurable physical performance outcomes, but all major trials were funded by one company (Amazentis).

What dose should I take of each?

NMN: 250 to 500 mg daily (most trial range). Urolithin A: 500 to 1,000 mg daily (trial range). Our NMN dosage guide covers the NMN question in detail.

Which is cheaper?

NMN. Budget NMN costs $17/month. Urolithin A starts around $50/month for less-studied brands and $70-$90/month for Mitopure.

Does Urolithin A raise NAD+?

Not directly. Urolithin A triggers mitophagy, not NAD+ synthesis. The two pathways are complementary.

What is Mitopure?

Mitopure is the branded Urolithin A ingredient made by Amazentis and sold under the Timeline brand. It is the form used in all major human trials.

Where can I learn more about NMN?

See our What Is NMN? guide, best NMN supplements, and our NMN product page.